<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>843</number>
    <updateDate>2025-03-28T17:46:13Z</updateDate>
    <updateDateIncludingText>2025-03-28T17:46:13Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <originChamberCode>H</originChamberCode>
    <type>HR</type>
    <introducedDate>2025-01-31</introducedDate>
    <congress>119</congress>
    <cdata>
      <constitutionalAuthorityStatementText>&lt;pre&gt;[Congressional Record Volume 171, Number 21 (Friday, January 31, 2025)][House]From the Congressional Record Online through the Government Publishing Office [&lt;a href="https://www.gpo.gov"&gt;www.gpo.gov&lt;/a&gt;]By Ms. BARRAGAN:H.R. 843.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8 of the United States Constitution[Page H433]&lt;/pre&gt;</constitutionalAuthorityStatementText>
    </cdata>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred To</name>
            <date>2025-01-31T15:02:00Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2025-01-31</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2025-01-31</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2025-01-31</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>B001300</bioguideId>
        <fullName>Rep. Barragán, Nanette Diaz [D-CA-44]</fullName>
        <firstName>Nanette</firstName>
        <lastName>Barragán</lastName>
        <party>D</party>
        <state>CA</state>
        <middleName>Diaz</middleName>
        <district>44</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects/>
      <policyArea>
        <name>Health</name>
        <updateDate>2025-03-04T13:15:22Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2025-01-31</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2025-03-28T17:45:23Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;strong&gt;Prompt Approval of Safe Generic Drugs Act&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;This bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a generic drug despite the omission of certain safety information from the generic drug's labeling.&lt;/p&gt;&lt;p&gt;Specifically, the FDA may not deem an abbreviated application for approval of a generic drug ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's patent or exclusivity protections. Similarly, a drug that is approved under this bill may not be considered mislabeled for lacking such safety information.&lt;/p&gt;&lt;p&gt;Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug (i.e., a generic drug). Currently,&amp;nbsp;the labeling for such a generic drug must generally be identical to that of the already-approved drug. This bill provides an exception to that requirement under the specified circumstances.&amp;nbsp;&lt;/p&gt;&lt;p&gt;For any drug approved under this bill, the FDA must require the drug's labeling to include any safety information that is necessary to assure safe use.&lt;/p&gt;</text>
        </cdata>
      </summary>
    </summaries>
    <title>Prompt Approval of Safe Generic Drugs Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>Prompt Approval of Safe Generic Drugs Act</title>
        <updateDate>2025-02-28T05:23:22Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Prompt Approval of Safe Generic Drugs Act</title>
        <updateDate>2025-02-28T05:23:19Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes.</title>
        <updateDate>2025-02-28T05:18:36Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2025-01-31T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-119hr843ih/xml/BILLS-119hr843ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2025-01-31</actionDate>
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
